Trial Profile
A Single Centre, Open Label Trial Investigating the Absorption, Metabolism and Excretion of Somapacitan After Single Subcutaneous Dosing in Healthy Male Subjects
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 01 Dec 2021
Price :
$35
*
At a glance
- Drugs Somapacitan (Primary)
- Indications Somatotropin deficiency
- Focus Pharmacokinetics
- Sponsors Novo Nordisk
- 01 Dec 2021 Results assessing the absorption, metabolism and excretion, as well as the pharmacokinetics (PK), of tritium-labelled somapacitan ([3H]-somapacitan). Healthy males received a single subcutaneous dose of 6 mg somapacitan containing [3H]-somapacitan 20 MBq, published in the European Journal of Pharmaceutical Sciences.
- 20 Mar 2018 Results assessing the absorption, metabolism and excretion in healthy male subjects after a single s.c. administration of tritium [3H]-somapacitan, presented at The 100th Annual Meeting of the Endocrine Society.
- 03 Feb 2017 Status changed from recruiting to completed.